A securities class action, styled Bridgewood v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08500 (S.D.N.Y), has been filed after MoonLake announced disastrous Phase 3 trial results for its only ...
Airports in New York, Los Angeles and Chicago are among 40 of the busiest across the U.S. where flights will be cut due to ...
Encouraging Phase 1 data on ZW191, an antibody-drug conjugate (ADC) targeting folate receptor-⍺ (FR⍺), presented at the AACR-NCI-EORTCConferenceFirst patient dosed in Phase 1 clinical trial of ZW251 ...
Electricity powers our lives, including our cars, phones, computers, and more, through the movement of electrons within a ...
The last two times we saw less than one-fifth of the U.S. economy expanding were the summer of 2020 and the winter of ...
Biohaven (BHVN) downgraded after FDA setback for VYGLXIA. Learn key risks, pipeline shifts, and what investors should watch ...
ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on CKD, today presented full results from the Phase 2 REGEN-007 trial ...
Immunocore reports third quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $103.7 million in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback